Cargando…

Pharmacokinetic modeling of [(11)C]flumazenil kinetics in the rat brain

BACKGROUND: Preferred models for the pharmacokinetic analysis of [(11)C]flumazenil human studies have been previously established. However, direct translation of these models and settings to animal studies might be sub-optimal. Therefore, this study evaluates pharmacokinetic models for the quantific...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopes Alves, Isadora, Vállez García, David, Parente, Andrea, Doorduin, Janine, Dierckx, Rudi, Marques da Silva, Ana Maria, Koole, Michel, Willemsen, Antoon, Boellaard, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321646/
https://www.ncbi.nlm.nih.gov/pubmed/28229437
http://dx.doi.org/10.1186/s13550-017-0265-4
_version_ 1782509717036204032
author Lopes Alves, Isadora
Vállez García, David
Parente, Andrea
Doorduin, Janine
Dierckx, Rudi
Marques da Silva, Ana Maria
Koole, Michel
Willemsen, Antoon
Boellaard, Ronald
author_facet Lopes Alves, Isadora
Vállez García, David
Parente, Andrea
Doorduin, Janine
Dierckx, Rudi
Marques da Silva, Ana Maria
Koole, Michel
Willemsen, Antoon
Boellaard, Ronald
author_sort Lopes Alves, Isadora
collection PubMed
description BACKGROUND: Preferred models for the pharmacokinetic analysis of [(11)C]flumazenil human studies have been previously established. However, direct translation of these models and settings to animal studies might be sub-optimal. Therefore, this study evaluates pharmacokinetic models for the quantification of [(11)C]flumazenil binding in the rat brain. Dynamic (60 min) [(11)C]flumazenil brain PET scans were performed in two groups of male Wistar rats (tracer dose (TD), n = 10 and pre-saturated (PS), n = 2). Time-activity curves from five regions were analyzed, including the pons (pseudo-reference region). Distribution volume (V(T)) was calculated using one- and two-tissue compartment models (1TCM and 2TCM) and spectral analysis (SA). Binding potential (BP(ND)) was determined from full and simplified reference tissue models with one or two compartments for the reference tissue (FRTM, SRTM, and SRTM-2C). Model preference was determined by Akaike information criterion (AIC), while parameter agreement was assessed by linear regression, repeated measurements ANOVA and Bland-Altman plots. RESULTS: 1TCM and 2TCM fits of regions with high specific binding showed similar AIC, a preference for the 1TCM, and good V(T) agreement (0.1% difference). In contrast, the 2TCM was markedly preferred and necessary for fitting low specific-binding regions, where a worse V(T) agreement (17.6% difference) and significant V(T) differences between the models (p < 0.005) were seen. The PS group displayed results similar to those of low specific-binding regions. All reference models (FRTM, SRTM, and SRTM-2C) resulted in at least 13% underestimation of BP(ND). CONCLUSIONS: Although the 1TCM was sufficient for the quantification of high specific-binding regions, the 2TCM was found to be the most adequate for the quantification of [(11)C]flumazenil in the rat brain based on (1) higher fit quality, (2) lower AIC values, and (3) ability to provide reliable fits for all regions. Reference models resulted in negatively biased BP(ND) and were affected by specific binding in the pons of the rat.
format Online
Article
Text
id pubmed-5321646
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-53216462017-03-07 Pharmacokinetic modeling of [(11)C]flumazenil kinetics in the rat brain Lopes Alves, Isadora Vállez García, David Parente, Andrea Doorduin, Janine Dierckx, Rudi Marques da Silva, Ana Maria Koole, Michel Willemsen, Antoon Boellaard, Ronald EJNMMI Res Original Research BACKGROUND: Preferred models for the pharmacokinetic analysis of [(11)C]flumazenil human studies have been previously established. However, direct translation of these models and settings to animal studies might be sub-optimal. Therefore, this study evaluates pharmacokinetic models for the quantification of [(11)C]flumazenil binding in the rat brain. Dynamic (60 min) [(11)C]flumazenil brain PET scans were performed in two groups of male Wistar rats (tracer dose (TD), n = 10 and pre-saturated (PS), n = 2). Time-activity curves from five regions were analyzed, including the pons (pseudo-reference region). Distribution volume (V(T)) was calculated using one- and two-tissue compartment models (1TCM and 2TCM) and spectral analysis (SA). Binding potential (BP(ND)) was determined from full and simplified reference tissue models with one or two compartments for the reference tissue (FRTM, SRTM, and SRTM-2C). Model preference was determined by Akaike information criterion (AIC), while parameter agreement was assessed by linear regression, repeated measurements ANOVA and Bland-Altman plots. RESULTS: 1TCM and 2TCM fits of regions with high specific binding showed similar AIC, a preference for the 1TCM, and good V(T) agreement (0.1% difference). In contrast, the 2TCM was markedly preferred and necessary for fitting low specific-binding regions, where a worse V(T) agreement (17.6% difference) and significant V(T) differences between the models (p < 0.005) were seen. The PS group displayed results similar to those of low specific-binding regions. All reference models (FRTM, SRTM, and SRTM-2C) resulted in at least 13% underestimation of BP(ND). CONCLUSIONS: Although the 1TCM was sufficient for the quantification of high specific-binding regions, the 2TCM was found to be the most adequate for the quantification of [(11)C]flumazenil in the rat brain based on (1) higher fit quality, (2) lower AIC values, and (3) ability to provide reliable fits for all regions. Reference models resulted in negatively biased BP(ND) and were affected by specific binding in the pons of the rat. Springer Berlin Heidelberg 2017-02-22 /pmc/articles/PMC5321646/ /pubmed/28229437 http://dx.doi.org/10.1186/s13550-017-0265-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Lopes Alves, Isadora
Vállez García, David
Parente, Andrea
Doorduin, Janine
Dierckx, Rudi
Marques da Silva, Ana Maria
Koole, Michel
Willemsen, Antoon
Boellaard, Ronald
Pharmacokinetic modeling of [(11)C]flumazenil kinetics in the rat brain
title Pharmacokinetic modeling of [(11)C]flumazenil kinetics in the rat brain
title_full Pharmacokinetic modeling of [(11)C]flumazenil kinetics in the rat brain
title_fullStr Pharmacokinetic modeling of [(11)C]flumazenil kinetics in the rat brain
title_full_unstemmed Pharmacokinetic modeling of [(11)C]flumazenil kinetics in the rat brain
title_short Pharmacokinetic modeling of [(11)C]flumazenil kinetics in the rat brain
title_sort pharmacokinetic modeling of [(11)c]flumazenil kinetics in the rat brain
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321646/
https://www.ncbi.nlm.nih.gov/pubmed/28229437
http://dx.doi.org/10.1186/s13550-017-0265-4
work_keys_str_mv AT lopesalvesisadora pharmacokineticmodelingof11cflumazenilkineticsintheratbrain
AT vallezgarciadavid pharmacokineticmodelingof11cflumazenilkineticsintheratbrain
AT parenteandrea pharmacokineticmodelingof11cflumazenilkineticsintheratbrain
AT doorduinjanine pharmacokineticmodelingof11cflumazenilkineticsintheratbrain
AT dierckxrudi pharmacokineticmodelingof11cflumazenilkineticsintheratbrain
AT marquesdasilvaanamaria pharmacokineticmodelingof11cflumazenilkineticsintheratbrain
AT koolemichel pharmacokineticmodelingof11cflumazenilkineticsintheratbrain
AT willemsenantoon pharmacokineticmodelingof11cflumazenilkineticsintheratbrain
AT boellaardronald pharmacokineticmodelingof11cflumazenilkineticsintheratbrain